Berita Terbaru             -  INFORMASI AWAL UNTUK TENAGA PROFESIONAL KESEHATAN TERKAIT KEAMANAN PRODUK YANG MENGANDUNG BAHAN AKTIF RANITIDIN            -  INFORMASI AWAL UNTUK TENAGA PROFESIONAL KESEHATAN TERKAIT KEAMANAN PRODUK YANG MENGANDUNG BAHAN AKTIF RANITIDIN            -  Tecentriq (Atezolizumab) and New Important Identified Risk of Immune-Related Myositis            -  Actemra┬« (Tocilizumab) and Risk of Hepatotoxicity            -  Buletin Berita MESO Volume 37, No 1 Edisi Juni 2019

Safety Communication

As part of pharmaceutical industry responsibility to ensure the safety aspects of the drugs marketed, PT Roche Indonesia  diseminate Dear Healthcare Professional Communication (DHPC) for healthcare professionals regarding contraindication recommendation  for patients who have dihydropyrimidine dehydrogenase (DPD) deficiency and addition of Warning and Precaution regarding recommendation for DPD deficiency testing based on local test available and current guideline.

Please refer to the letter for details.


Download : DHPC Xeloda.zip
How do you think the content and appearance of this website?




logo dsras Email Rapid Alert System

Selamat email anda telah berlangganan untuk selalu mendapatkan informasi terkini mengenai keamanan obat yang beredar di Indonesia.

 

logo dsras Email Rapid Alert System

Anda ingin berhenti berlangganan untuk selalu mendapatkan informasi terkini mengenai keamanan obat yang beredar di Indonesia?